United Therapeutics (UTHR) Amortization of Deferred Charges (2009 - 2016)

United Therapeutics has disclosed Amortization of Deferred Charges across 8 years of filings, most recently posting $100000.0 for Q1 2016.

• In Q1 2016, Amortization of Deferred Charges fell 95.0% year-over-year to $100000.0; the TTM figure through Jun 2016 stood at $941000.0 (down 91.46% YoY), while the FY2015 annual figure was $5.9 million, down 52.3% from the prior year.
• Amortization of Deferred Charges came in at $100000.0 for Q1 2016 at United Therapeutics, down from $433000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $3.4 million in Q3 2014 to a low of $100000.0 in Q1 2016.
• Average Amortization of Deferred Charges over 5 years is $2.5 million, with a median of $3.0 million recorded in 2012.
• Year-over-year, Amortization of Deferred Charges jumped 47.5% in 2013 and plunged 95.0% in 2016.
• Over 5 years, Amortization of Deferred Charges stood at $2.2 million in 2012, then jumped by 47.5% to $3.2 million in 2013, then declined by 21.98% to $2.5 million in 2014, then plunged by 82.6% to $433000.0 in 2015, then plunged by 76.91% to $100000.0 in 2016.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $100000.0 in Q1 2016, $433000.0 in Q4 2015, and $408000.0 in Q3 2015.